| Literature DB >> 30032678 |
Bei Hu1, Peter Thall2, Denái R Milton2, Koji Sasaki3, Qaiser Bashir4, Nina Shah4, Krina Patel5, Uday Popat4, Chitra Hosing4, Yago Nieto4, Pei Lin6, Ruby Delgado4, Jeffrey Jorgensen6, Elisabet Manasanch5, Donna Weber5, Sheeba Thomas5, Robert Z Orlowski5, Richard Champlin4, Muzaffar H Qazilbash4.
Abstract
The aim of our study was to determine the impact of high-risk disease (HRD) and MRD on outcomes in myeloma patients receiving bortezomib-based induction followed by autologous hematopoietic stem cell transplant (auto-HSCT). HRD included t(4:14), t(14;16), del 17p, del 1p and/or amplification 1q by cytogenetics/FISH; all others were standard-risk disease (SRD). A subset of 165 newly diagnosed myeloma patients in a 2:1 ratio of HRD:SRD was generated using propensity score based nearest neighbor matching. Multiparametric flow cytometry (MFC) was used to detect MRD after auto-HSCT in select patients. MRD+ status at 3 months post auto-HSCT (hazard ratio (HR = 4.23, p = .028) and HRD (HR = 1.72, p = .026) were associated with a shorter PFS. Similarly, MRD+ 3 months post auto-HSCT (HR = 6.93, p = .08) and HRD (HR = 3.54, p < .001) and were associated with a shorter OS. Despite bortezomib-based induction, upfront auto-HSCT, and use of maintenance therapy, PFS and OS remained worse in MRD+ and HRD patients.Entities:
Keywords: Multiple myeloma; autologous stem cell transplant; flow cytometry; high-risk cytogenetics; minimal residual disease; nearest neighbor matching
Mesh：
Substances：
Year: 2018 PMID： 30032678 DOI： 10.1080/10428194.2018.1485908
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022